From GlobeNewswire: 2025-06-20 16:01:00

Wave Life Sciences presented data on WVE-007, a potential obesity treatment, showing significant reduction in fat with muscle preservation. The treatment targets Activin E, reducing inflammation and potentially lowering risk for type 2 diabetes and heart disease. The presentation highlighted the ability of WVE-007 to induce healthy weight loss without affecting lean muscle mass. Human genetics support INHBE as a therapeutic target, with protective variants showing benefits for cardiometabolic health. The preclinical data demonstrated promising results, with potential for clinical translation and transformation of obesity treatment paradigms.



Read more at GlobeNewswire: Wave Life Sciences Announces Oral Presentation of